Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

On the heels of the launch of an online direct-to-patient (DTP) program offering discounted Eliquis to certain U.S. patients, Bristol Myers Squibb is putting Sotyku at the center of its next DTP ...

Windows 11 is available for download worldwide. Microsoft has released it as a free upgrade, which means you do not need to pay to upgrade your computer to Windows 11. It is available for free ...

DIY Tattoo Machine Made from a Pen – Easy Tutorial You Won’t Believe! Nicole Kidman Files for Divorce from Keith Urban After 19 Years of Marriage Gen Z is reviving this boring job that millennials and ...

Bristol Myers Squibb, Board Chair of BMS and CEO Christopher Boerner, PhD, have committed the pharma giant to investing $40 billion over the next five years toward U.S. research and development (R&D), ...

Roughly two years after securing a former Novartis facility in Illinois to support its CAR-T cancer treatments Breyanzi and Abecma, Bristol Myers Squibb is rethinking its operations at the site. BMS ...

Automotive BMS must undergo rigorous testing to verify that it meets stringent performance and safety standards. BMS emulation involves using hardware and software tools to simulate the behavior of a ...

Details on a BMS based on electrochemical impedance spectroscopy (EIS). BMS advances to keep pace with EV rising complexity. Building better battery models based on EIS characterization. The ...

Battery management system (BMS) hardware and software continue to evolve as electric vehicles (EVs) transition to 800-V Li-ion battery systems comprising around 200 individual cells connected in ...

Bristol Myers Squibb is axing another big bet from the Caforio era, terminating a deal for Agenus’ TIGIT bispecific antibody three years after paying $200 million to buy into the program. Agenus ...

Bristol Myers Squibb has had a whiplash change of heart on its BCMA bispecific T-cell engager, halting (PDF) further development months after filing to run a phase 3 trial. The Big Pharma disclosed ...